Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesc Bosch

Showing results (131-140 of 170) with videos related to

Pageof 17
Sort By:
Hematological Oncology|February 18, 2015
A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemiaIsabel González-Gascón Y Marín, María Hernández-Sánchez, Ana-Eugenia Rodríguez-Vicente, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 29, 2026
Response to the letter to the editor entitled "The precision of a report on precision"Pilar Mur, Anna Pozuelo, Josep Tabernero, et al.
Leukemia|May 7, 2025
Myelodysplastic neoplasms with ring sideroblasts without SF3B1 mutations in adults: enrichment of germline variants in congenital sideroblastic anemia genesSandra Novoa-Jáuregui, Sandra Huber, Maria Gabarrós-Subirà, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2021
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation StudyLihua E Budde, Sarit Assouline, Laurie H Sehn, et al.
British Journal of Haematology|July 23, 2013
Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletionAnna Puiggros, Julio Delgado, Ana Rodriguez-Vicente, et al.
Blood Advances|April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphomaNancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.
Haematologica|March 11, 2021
Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patientsSilvia Ramos-Campoy, Anna Puiggros, Sílvia Beà, et al.
Blood|April 24, 2024
Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphomaGilles Crochet, Gloria Iacoboni, Audrey Couturier, et al.
Eclinicalmedicine|June 6, 2024
Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)Pau Abrisqueta, Eva González-Barca, Christelle Ferrà, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2020
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell LymphomaLeo I Gordon, Jason B Kaplan, Rakesh Popat, et al.
Pageof 17

Showing results (131-140 of 170) with videos related to

Sort By:
Pageof 17
Hematological Oncology|February 18, 2015
A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemiaIsabel González-Gascón Y Marín, María Hernández-Sánchez, Ana-Eugenia Rodríguez-Vicente, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 29, 2026
Response to the letter to the editor entitled "The precision of a report on precision"Pilar Mur, Anna Pozuelo, Josep Tabernero, et al.
Leukemia|May 7, 2025
Myelodysplastic neoplasms with ring sideroblasts without SF3B1 mutations in adults: enrichment of germline variants in congenital sideroblastic anemia genesSandra Novoa-Jáuregui, Sandra Huber, Maria Gabarrós-Subirà, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2021
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation StudyLihua E Budde, Sarit Assouline, Laurie H Sehn, et al.
British Journal of Haematology|July 23, 2013
Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletionAnna Puiggros, Julio Delgado, Ana Rodriguez-Vicente, et al.
Blood Advances|April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphomaNancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.
Haematologica|March 11, 2021
Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patientsSilvia Ramos-Campoy, Anna Puiggros, Sílvia Beà, et al.
Blood|April 24, 2024
Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphomaGilles Crochet, Gloria Iacoboni, Audrey Couturier, et al.
Eclinicalmedicine|June 6, 2024
Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)Pau Abrisqueta, Eva González-Barca, Christelle Ferrà, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2020
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell LymphomaLeo I Gordon, Jason B Kaplan, Rakesh Popat, et al.
Pageof 17